Navigation Links
Alternatives Available Nationwide to Addictive Benzodiazepines for Anxiety
Date:1/2/2017

BIRMINGHAM, Ala., Jan. 2, 2017 /PRNewswire/ -- The pharmaceutical research company TPD LLC (Trends in Pharma Development) announced that the PanX® new class of medicines intended for the treatment of anxiety are now available nationwide as prescription compounded drugs.

Two US patents 9,446,030 and 9,517,231 were recently issued to the company in September and December, respectively.  The patents broadly cover dual drug combinations of historically-safe active ingredients that are being re-purposed for the treatment of anxiety disorders, such as social anxiety disorder, panic, and PTSD. The combinations were designed to suppress the multiple symptoms of acute anxiety.

The PanX® drugs are intended as "as needed" alternatives to benzodiazepines (e.g., Xanax® or Valium®) that are addictive, have the potential for abuse, and are Controlled Substances.  However, the active ingredients in the PanX® brand, beta blockers and antiemetic motion sickness agents, have no history of addiction or abuse in five decades of prescription or over-the-counter use.  The company's goal for the patented new class of medicines is to provide effective, fast-acting, yet safer alternatives to benzodiazepines.

According to a leading authority on anxiety therapies, Professor Charles B. Nemeroff, MD PhD, Chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami, "A number of patients with prominent anxiety symptoms do not respond or cannot tolerate currently available treatments. This novel approach combining two medications with distinct mechanisms of action has the potential to fill an important niche in the management of such patients."

TPD has contracted with Pine Pharmaceuticals and Pine Pharmacy of New York, and Custom Meds of Florida to produce the products as prescription compounded drugs.  The combination drug products are available in 49 states as patient-specific prescriptions by mail order and/or as "office use" medications administered by physicians, for instance in medical procedures when patients are anxious or fearful.  For additional information see www.PanX.us.

TPD is also pursuing the clinical development of selected PanX® drugs to seek product approval by the US Food and Drug Administration (FDA).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alternatives-available-nationwide-to-addictive-benzodiazepines-for-anxiety-300384404.html


'/>"/>
SOURCE TPD LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. RI Physical Therapist Discusses Alternatives to Rising Opioid Use
2. EpiBiome Secures $6 Million Series A Financing to Develop Alternatives to Small-Molecule Antibiotics for Agriculture
3. KaloBios to Reduce Workforce, Explore Strategic Alternatives
4. The Manufacturer of the SynCardia Total Artificial Heart has Hired Investment Bank Canaccord Genuity, Inc. to Advise the BOD on Strategic Alternatives to Maximize Stakeholder Equity
5. Unilife Announces Review of Strategic Alternatives
6. As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation
7. Pessaries and Other Vaginal Mesh Alternatives Discussed by Life Care Solutions Group
8. BioNet Received Thai FDA Approval of the Worlds Only Available Recombinant Monovalent Acellular Pertussis (aP) Vaccine
9. Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option
10. Zymo Research Announces Nucleic Acid Purification Kits Now Available on Amazon.com
11. In-home PFT Testing Is Now Available to Patients with ndd Medicals Mobile EasyOne Pro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
(Date:4/21/2017)... Colo. (PRWEB) , ... April 21, 2017 , ... The ... the Flex House, the next project in the company’s esteemed VISION House demonstration project ... homeowners use exactly the amount of resources they need to live affordably and abundantly ...
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility in ... Kong to support teaching, learning and research. It is also the largest research centre ... Kong. , With an area of 620 square metres and more than 50 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens ... of International Trade, the UK’s most prestigious award for business success. The ... of total revenues and has grown by a total of 400% over the ...
Breaking Medicine News(10 mins):